Blood component recalls and market withdrawals: Frequency, reasons, and management in the United States

Glenn Ramsey*

*Corresponding author for this work

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

In a previous article, we reviewed the management of blood component recalls and withdrawals (G. Ramsey. Transfusion Med Rev 2004;18:36-45). Since then, US rates of recall and biological product deviation for blood components have improved significantly, particularly with regard to reduced recalls for donor infectious disease risks or testing. However, analysis of the current data from the US Food and Drug Administration suggests that 1 (0.4%) in 250 blood components is involved in market withdrawals and quarantines, with 1 in 5800 components formally recalled. Most of these units, unfortunately, had already have been transfused. The US Food and Drug Administration has issued several recent guidances that address transfusion service actions for dealing with specific infectious disease problems. This present article updates our 2004 recommendations as to when to notify physicians about transfused nonconforming blood components.

Original languageEnglish (US)
Pages (from-to)82-90
Number of pages9
JournalTransfusion Medicine Reviews
Volume27
Issue number2
DOIs
StatePublished - Apr 2013

ASJC Scopus subject areas

  • Hematology
  • Clinical Biochemistry
  • Biochemistry, medical

Fingerprint Dive into the research topics of 'Blood component recalls and market withdrawals: Frequency, reasons, and management in the United States'. Together they form a unique fingerprint.

Cite this